Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

Introducing Tenable Hexa AI: The Agentic Engine That Supercharges Security Productivity and Accelerates Risk Reduction

View original at globenewswire.com
Introducing Tenable Hexa AI: The Agentic Engine That Supercharges Security Productivity and Accelerates Risk Reduction SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- RSA Conference Booth at #6155 — Tenable® Holdings, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Tenable Exposure Data Fabric is the industry's most comprehensive repository of contextualized exposure data and intelligence

    60% confidence

  • Tenable protects over 40,000 customers around the globe

    60% confidence

  • Tenable Hexa AI marries an agentic orchestration engine to the powerful contextual exposure data fabric of Tenable One, automating complex tasks and orchestrating fixes across the enterprise, neutralizing exposures before they're exploited.

    60% confidence

  • There has never been a greater need to have an agentic system preemptively fixing issues before they are exploited. As AI-based attacks accelerate, the window from discovery to exploitation has effectively vanished.

    60% confidence

  • Tenable Hexa AI has fundamentally shifted how we deploy our security resources, powering and scaling efficiency across workflows. Reclaiming two days a month on a single process like asset tagging is a massive win for our team.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com